高级检索
当前位置: 首页 > 详情页

Original In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer

| 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [2]Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [3]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, The People’s Republic of China [4]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, The People’s Republic of China [5]Ninth School of Clinical Medicine, Peking University, Beijing 100038, The People’s Republic of China [6]Department of Intensive Care Unit, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [7]Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [8]Department of General Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, The People’s Republic of China [9]Yunnan University, Kunming 650091, Yunnan, The People’s Republic of China [10]Department of General Surgery, The Affiliated Hospital of Yunnan University, Kunming 650091, Yunnan, The People’s Republic of China
出处:
ISSN:

关键词: Colon cancer prediction prognosis gene signature risk model

摘要:
Colon cancer is one of the most common cancers in digestive system, and its prognosis remains unsat-isfactory. Therefore, this study aimed to identify gene signatures that could effectively predict the prognosis of colon cancer patients by examining the data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database. LASSO-Cox regression analysis generated a five-gene signature (DCBLD2, RAB11FIP1, CTLA4, HOXC6 and KRT6A) that was associated with patient survival in the TCGA cohort. The prognostic value of this gene signature was further validated in two independent GEO datasets. GO enrichment revealed that the function of this gene signature was mainly associated with extracellular matrix organization, collagen-containing extracellular matrix, and extracellular matrix structural constituent. Moreover, a nomogram was established to facilitate the clini-cal application of this signature. The relationships among the gene signature, mutational landscape and immune infiltration cells were also investigated. Importantly, this gene signature also reliably predicted the overall survival in IMvigor210 anti-PD-L1 cohort. In addition to the bioinformatics study, we also conducted a series of in vitro ex-periments to demonstrate the effect of the signature genes on the proliferation, migration, and invasion of colon cancer cells. Collectively, our data demonstrated that this five-gene signature might serve as a promising prognostic biomarker and shed light on the development of personalized treatment in colon cancer patients.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [2]Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [3]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, The People’s Republic of China [4]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, The People’s Republic of China [5]Ninth School of Clinical Medicine, Peking University, Beijing 100038, The People’s Republic of China
通讯作者:
通讯机构: [1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [2]Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China [3]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, The People’s Republic of China [4]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, The People’s Republic of China [5]Ninth School of Clinical Medicine, Peking University, Beijing 100038, The People’s Republic of China [10]Department of General Surgery, The Affiliated Hospital of Yunnan University, Kunming 650091, Yunnan, The People’s Republic of China [*1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10th Tieyi Road, Haidian District, Beijing 100038, The People’s Republic of China. [*2]Department of General Surgery, The Affiliated Hospital of Yunnan University, No. 176 Qingnian Road, Wuhua District, Kunming 650091, Yunnan, The People’s Republic of China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)